“EVALUATION OF EFFICACY OF VARUNI TAILA (CITRULLUS COLOCYNTHIS SCHARD) IN KAMPAVATA WITH SPECIAL REFERENCE TO PARKINSON’S DISEASE-A COMPARATIVE CLINICAL STUDY”
Dr. Noor Fathima*, Dr. Shivaprasad Huded, Dr. Nataraj H. R. and Dr. Satish Pai
ABSTRACT
Parkinson’s disease (PD) is the most common form of a group of progressive neurodegenerative disorders characterized by bradykinesia, rest tremor, muscular rigidity, shuffling gait, and flexed posture.[1] Most of these features match with the Ayurvedic description of the disease KAMPAVATA.[2,3] Worldwide incidence of PD is estimated to be around 7 to 10 million.[4] Its peak age of onset is in the early 60s[1], progressively debilitating the affected individual. Current drug therapies for human PD with Levodopa or various dopamine receptor agonists offer symptomatic relief and appear to have little effect on the neurodegenerative process.[5] More than 50% of patients with PD
treated over 5 years with Levodopa will develop complications such as motor fluctuations and dyskinesia’s. In this scenario, slowing the progression of PD through neuroprotective or restorative therapy is a major focus of research. From a pharmacologic standpoint, current strategies involve interrupting the cascade of biochemical events that leads to death of dopaminergic cells.[1] Hence, the current study aims at finding such an activity in an herb INDRAVARUNI – Citrullus colocynthis (which is prescribed in a classical Ayurvedic text for the management of KAMPAVATA[6]) with willing human beings.
Keywords: INDRAVARUNI – Citrullus colocynthis, KAMPAVATA.
[Download Article]
[Download Certifiate]